

Cellnovo acquires commercial license for Artificial Pancreas Technology from TypeZero Technologies

PARIS and CHARLOTTESVILLE, Va., April 18, 2017 – Cellnovo Group (“Cellnovo” CLNV: EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero’s Artificial Pancreas (AP) technology into Cellnovo’s mobile diabetes management systems.

The non-exclusive worldwide agreement allows Cellnovo to commercialize a Cellnovo-TypeZero product in the future. Integration efforts are currently underway with a product launch expected in 2018. No financial terms have been disclosed.

TypeZero’s AP software, known as inControl AP, will be incorporated directly into Cellnovo’s Bluetooth-enabled micropump. inControl AP continuously monitors blood glucose levels via a smartphone application and automatically delivers corrections to regulate blood sugar levels through an integrated insulin pump.

“Our partnership with TypeZero brings us another step closer to delivering one of the first end-to-end diabetes management systems,” said Sophie Baratte, Chief Executive Officer of Cellnovo. “We are confident that this strategic collaboration will result in a sophisticated product that improves the quality of life for patients with type 1 diabetes.”

“The future of diabetes care is rapidly progressing toward integrated solutions that simplify the device burden that people with type 1 diabetes face,” said Chad Rogers, Chief Executive Officer of TypeZero. “The Cellnovo mobile diabetes management system is an ideal platform for artificial pancreas system development because of its real-time connected data and discreetness to suit the needs and lifestyle of patients. I believe the combination of our artificial pancreas technology with Cellnovo’s advanced pump system can fundamentally shift the way we treat type 1 diabetes, and we’re excited about that possibility.”

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop



precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time.

CellNovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV



About TypeZero Technologies, Inc.

The world leader in clinically tested artificial pancreas solutions, TypeZero Technologies is a digital health and personalized medicine company dedicated to revolutionizing the treatment and management of diabetes. TypeZero is combining next-generation data science techniques, proven metabolic models, and modern engineering practices to develop customized analytics tools and blood glucose control solutions to help people with diabetes improve their health and lives. TypeZero's current solutions include a smartphone-based artificial pancreas system, therapy optimization tools for health care providers, and advisory applications for smart insulin pens. To learn more, visit www.typezero.com.

Contact

CellNovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Tristan Roquet Montégon
+ 33 1 44 71 00 16

Consilium Strategic Communications

Media Relations in United Kingdom
Chris Gardner, Chris Welsh, Laura Thornton
+44 20 3709 5700
cellnovo@consilium.com

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

TypeZero Technologies, Inc.

Meagan Collins
Senior Operations Manager
mcollins@typezero.com
(434) 284-8919